Redhill Biopharma Ltd. (RDHL)

Nasdaq: RDHL · Pharmaceutical Preparations · Tel Aviv, IL · filing with the SEC since 2012

Full chart Alerts Compare

Grade3.9

◀ Past 5.1● Present 3.5▶ Future 3.6

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Redhill Biopharma Ltd.

Nine metrics read from its own filings, by tense

Headline grade

3.9/10

◀ Past5.125% of the headline

● Present3.535% of the headline

▶ Future3.640% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.1/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 22% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Redhill Biopharma Ltd.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

6.1/10

What has it actually done, year after year?

+140.3% a year over 10 filed years; profitable in 1 of 10.

weight 45% of this tense · 61st percentile among 323 sector filers · read for its customers

From the record

Redhill Biopharma Ltd.'s 10 filed years say what it did: revenue went from $3 thousand in fiscal 2015 to $8 million in fiscal 2024, up 140.3% a year; it rose in 6 of 9 years; the deepest fall was 92% from fiscal 2021 to fiscal 2023; net income was positive in 1 of 10 of those years (its annual reports).

What it rests on

revenue growth over the filed span140.3%top 5% of its family
the share of years revenue rosetop 41% of its family
the share of filed years with a profittop 42% of its family
the deepest fall from a revenue peak92.4%bottom 32% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

1.5/10

How has it treated the people who own it?

SI estimate 1.5/10, confidence 35 of 100 (one part).

weight 33% of this tense · 15th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 15% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Redhill Biopharma Ltd.'s shareholder treatment is put at 1.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 15% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.5/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

2.5/10

Is it financially healthy right now?

Leverage 126%: owes 126¢ per asset dollar.

weight 45% of this tense · 25th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2024-12-31, Redhill Biopharma Ltd.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 27 cents per dollar of everything the company owns. Leverage: it owed about 126 cents per dollar of assets, and net share issuance: its share count grew 375.6% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 8% of its family
gross profit against assetstop 46% of its family
the share count against the year beforebottom 13% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

3.4/10

How strong is its position in its industry?

bottom 33% of 315 in its family; net margin -102.8%.

weight 22% of this tense · 33rd percentile among 315 sector filers · read for its customers

From the record

Redhill Biopharma Ltd.'s standing among 315 graded names in its industry family: revenue of $8 million in fiscal 2024 ranks in the bottom 40% by size; a net margin of -102.8% ranks in the top 47%; revenue growth of -54.6% a year over the last 3 filed years ranks in the bottom 7% (its annual reports).

What it rests on

revenue against the family$8.0Mbottom 40% of its family
net margin-102.8%top 47% of its family
three-year revenue growth-54.6%bottom 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: family median, 371 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Redhill Biopharma Ltd.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

3.6/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed

4.0/10

How much room does it have to grow?

bottom 40% of 273 in its family for room to expand.

weight 33% of this tense · 40th percentile among 273 sector filers · read for itself

From the record

Redhill Biopharma Ltd.'s room to grow, from the newest filed statements (fiscal 2024): cash of $5 million against no long-term debt tagged leaves 25.6% of its assets as net cash, bottom 48% of its family; cash from operations less capital spending is -116.6% of revenue (bottom 48%); a gross margin of 60.3% (bottom 38%); research spending of 19.7% of revenue (bottom 25%) (its annual report).

What it rests on

cash less debt against assets25.6%bottom 48% of its family
cash from operations less capital spending against revenue-116.6%bottom 48% of its family
gross margin60.3%bottom 38% of its family
research spending against revenue19.7%bottom 25% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

2.1/10

What could actually drive growth from here?

bottom 21% of 306 in its family for growth drivers.

weight 45% of this tense · 21st percentile among 306 sector filers · read for its customers

From the record

Redhill Biopharma Ltd.'s growth drivers, from the filed years to fiscal 2024: revenue grew -54.6% a year over the last three filed years against 140.3% over all 10, slowing (bottom 1% of its family); the newest year grew 23.1% (top 35%); research spending grew -62.2% a year (bottom 2%); capital spending grew -57.2% a year (bottom 16%) (its annual reports). Redhill Biopharma Ltd. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span-194.9 points a yearbottom 1% of its family
the newest year's revenue growth23.1%top 35% of its family
three-year growth of research spending-62.2%bottom 2% of its family
three-year growth of capital spending-57.2%bottom 16% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

6.3/10

Did its newest year beat what its own record pointed to?

top 37% of 233 in its family for expectations against reality.

weight 22% of this tense · 63rd percentile among 233 sector filers · read for its shareholders

From the record

Redhill Biopharma Ltd.'s newest year against its own record: revenue of $8 million in fiscal 2024 came in 346.8% above the $2 million its prior three years' pace pointed to (top 9% of its family); net income of $8 million against a prior three-year average of $48 million (top 21%); a net margin of a loss larger than its revenue against 45.4% before (bottom 19%) (its annual reports).

What it rests on

revenue against the prior three years' pace346.8%top 9% of its family
net income against the prior three years' average+83%top 21% of its family
net margin against its prior averagedown more than 100 pointsbottom 19% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton RDHL · research, not advice